Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer. Brian Piper joined the company with over 25 years of biopharmaceutical experience, most recently serving as CFO of Scorpion Therapeutics and its spin-off, Antares Therapeutics. His background includes significant leadership roles at Prelude Therapeutics, Aevi Genomic Medicine, and a 13-year tenure at Shire Pharmaceuticals.

This leadership change comes at a critical juncture as Sana Biotechnology Inc. (NASDAQ:SANA) approaches several major clinical milestones. Over the next 12 to 18 months, the company expects to generate initial clinical data for SC451, its hypoimmune-modified islet cell therapy for Type 1 diabetes, and SG293, an in vivo CAR T therapy for B-cell related diseases. These data readouts are viewed by management as significant value inflection points for the company’s proprietary platforms.

Financially, Sana Biotechnology’s most recent reports from late 2025 indicated a strengthened balance sheet following ~$133 million in equity financing. At that time, the company projected its cash runway to extend into late 2026. Piper’s immediate focus will involve overseeing disciplined capital allocation and maintaining a strong financial position to support the continued development of Sana Biotechnology’s in vivo CAR T and hypoimmune cell therapy portfolios.

Sana Biotechnology Inc. (NASDAQ:SANA) is a biotechnology company that utilizes engineered cells as medicines in the US. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs.